These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15842977)

  • 1. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.
    Kuivenhoven JA; de Grooth GJ; Kawamura H; Klerkx AH; Wilhelm F; Trip MD; Kastelein JJ
    Am J Cardiol; 2005 May; 95(9):1085-8. PubMed ID: 15842977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits.
    Zhang B; Fan P; Shimoji E; Xu H; Takeuchi K; Bian C; Saku K
    Arterioscler Thromb Vasc Biol; 2004 Oct; 24(10):1910-5. PubMed ID: 15331428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
    Barter PJ; Kastelein JJ
    J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.
    de Grooth GJ; Kuivenhoven JA; Stalenhoef AF; de Graaf J; Zwinderman AH; Posma JL; van Tol A; Kastelein JJ
    Circulation; 2002 May; 105(18):2159-65. PubMed ID: 11994249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.
    Ballantyne CM; Miller M; Niesor EJ; Burgess T; Kallend D; Stein EA
    Am Heart J; 2012 Mar; 163(3):515-21, 521.e1-3. PubMed ID: 22424025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.
    Clark RW
    Curr Opin Pharmacol; 2006 Apr; 6(2):162-8. PubMed ID: 16487747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
    de Grooth GJ; Zerba KE; Huang SP; Tsuchihashi Z; Kirchgessner T; Belder R; Vishnupad P; Hu B; Klerkx AH; Zwinderman AH; Jukema JW; Sacks FM; Kastelein JJ; Kuivenhoven JA
    J Am Coll Cardiol; 2004 Mar; 43(5):854-7. PubMed ID: 14998629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.
    Okamoto H; Yonemori F; Wakitani K; Minowa T; Maeda K; Shinkai H
    Nature; 2000 Jul; 406(6792):203-7. PubMed ID: 10910363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.
    Clark RW; Sutfin TA; Ruggeri RB; Willauer AT; Sugarman ED; Magnus-Aryitey G; Cosgrove PG; Sand TM; Wester RT; Williams JA; Perlman ME; Bamberger MJ
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):490-7. PubMed ID: 14739125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia.
    Hermann F; Enseleit F; Spieker LE; Périat D; Sudano I; Hermann M; Corti R; Noll G; Ruschitzka F; Lüscher TF
    Thromb Res; 2009; 123(3):460-5. PubMed ID: 18789492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.
    Boekholdt SM; Sacks FM; Jukema JW; Shepherd J; Freeman DJ; McMahon AD; Cambien F; Nicaud V; de Grooth GJ; Talmud PJ; Humphries SE; Miller GJ; Eiriksdottir G; Gudnason V; Kauma H; Kakko S; Savolainen MJ; Arca M; Montali A; Liu S; Lanz HJ; Zwinderman AH; Kuivenhoven JA; Kastelein JJ
    Circulation; 2005 Jan; 111(3):278-87. PubMed ID: 15655129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
    Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians.
    Forrester JS; Makkar R; Shah PK
    Circulation; 2005 Apr; 111(14):1847-54. PubMed ID: 15824213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic implications of cholesteryl ester transfer protein inhibitors in hyperlipidemia and low high-density lipoprotein-cholesterolemia.
    Inazu A; Mabuchi H
    Curr Opin Investig Drugs; 2003 Mar; 4(3):291-7. PubMed ID: 12735230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction.
    Schaefer EJ; Asztalos BF
    Curr Opin Lipidol; 2006 Aug; 17(4):394-8. PubMed ID: 16832162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: in vivo studies in rabbits.
    Kee P; Caiazza D; Rye KA; Barrett PH; Morehouse LA; Barter PJ
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):884-90. PubMed ID: 16373610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver.
    Gauthier A; Lau P; Zha X; Milne R; McPherson R
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2177-84. PubMed ID: 16123327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin.
    Marschang P; Sandhofer A; Ritsch A; Fiŝer I; Kvas E; Patsch JR
    J Intern Med; 2006 Aug; 260(2):151-9. PubMed ID: 16882279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.